Company / Net Income
Edwards Lifesciences Net Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$1.1B
FY2025
5-year range
$1.1B / $4.2B
FY2021-FY2025
Trend
-74.3%
vs FY2024
Sector context
#24 of 164
Health Care
What the data says
Edwards Lifesciences's net income of $1.1B is higher than 85% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 5 years, ranging from $1.1B in FY2025 to $4.2B in FY2024.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 3-year CAGR of -11.0%. Top quartile in the Health Care sector.
Declined from $1.5B to $1.1B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -11.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 164This company $1.1B Sector average $467.5M
▼
+129.6% above sector average
Key checks
Key Insights
- 3-year CAGR of -11.0%, indicating a declining trend.
- In FY2025, net income decreased 74.3% year-over-year.
- Ranks #24 out of 164 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | -74.3% |
| FY2024 | $4.2B | +177.7% |
| FY2023 | $1.5B | -1.2% |
| FY2022 | $1.5B | +1.3% |
| FY2021 | $1.5B | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026